Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities

Acquisitions

▤ Summary

Azenta announced strategic investments to strengthen GENEWIZ’s gene synthesis capabilities. The company signed an exclusive licensing agreement with Elegen for cell-free DNA synthesis technology and acquired SynPlexity for pooled gene assembly technology. These moves expand high-throughput discovery workflows and support biologics discovery, synthetic biology, protein engineering, and AI-enabled drug discovery. Azenta expects the combined technologies to improve quality, speed, scalability, and regional production capacity for customers.

◇ AskAI Classifications

Sectors
Life Sciences and Pharmaceutical Life Sciences Management Life Sciences Analytics
Functions
No functions detected

▦ Linked Companies

Azenta Life Sciences
$500M to $1B